Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{1ef07022f677422b8f55f692d8e36238,
title = "Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis",
abstract = "The objectives were to study the expression of very late antigen (VLA)-4, melanoma cell adhesion molecule-1 (MCAM-1) and activated leukocyte cell adhesion molecule (ALCAM) on CD4+ T cells during natalizumab treatment and to investigate the association with disease activity. We find that subgroups of autoreactive T cells are retained in peripheral blood, in particular MOG-reactive CD4+ T cells expressing MCAM-1. The expression of MCAM-1 or ALCAM on CD4+ T cells was, however, not clearly associated with disease activity (clinical or MRI) during natalizumab treatment. We confirm upregulation of MCAM-1 on CD4+ T cells during natalizumab treatment while VLA-4 is downregulated.",
keywords = "Adult, Aged, CD146 Antigen/biosynthesis, CD4-Positive T-Lymphocytes/drug effects, Cohort Studies, Female, Gene Expression, Humans, Immunologic Factors/administration & dosage, Infusions, Intravenous, Male, Middle Aged, Multiple Sclerosis/blood, Natalizumab/administration & dosage, Prospective Studies, Young Adult",
author = "Petersen, {E R} and C Ammitzb{\o}ll and S{\o}ndergaard, {H B} and Oturai, {A B} and S{\o}rensen, {P S} and Nilsson, {A C} and L B{\"o}rnsen and {von Essen}, M and F Sellebjerg",
note = "Copyright {\textcopyright} 2019 Elsevier B.V. All rights reserved.",
year = "2019",
month = dec,
day = "15",
doi = "10.1016/j.jneuroim.2019.577085",
language = "English",
volume = "337",
pages = "577085",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis

AU - Petersen, E R

AU - Ammitzbøll, C

AU - Søndergaard, H B

AU - Oturai, A B

AU - Sørensen, P S

AU - Nilsson, A C

AU - Börnsen, L

AU - von Essen, M

AU - Sellebjerg, F

N1 - Copyright © 2019 Elsevier B.V. All rights reserved.

PY - 2019/12/15

Y1 - 2019/12/15

N2 - The objectives were to study the expression of very late antigen (VLA)-4, melanoma cell adhesion molecule-1 (MCAM-1) and activated leukocyte cell adhesion molecule (ALCAM) on CD4+ T cells during natalizumab treatment and to investigate the association with disease activity. We find that subgroups of autoreactive T cells are retained in peripheral blood, in particular MOG-reactive CD4+ T cells expressing MCAM-1. The expression of MCAM-1 or ALCAM on CD4+ T cells was, however, not clearly associated with disease activity (clinical or MRI) during natalizumab treatment. We confirm upregulation of MCAM-1 on CD4+ T cells during natalizumab treatment while VLA-4 is downregulated.

AB - The objectives were to study the expression of very late antigen (VLA)-4, melanoma cell adhesion molecule-1 (MCAM-1) and activated leukocyte cell adhesion molecule (ALCAM) on CD4+ T cells during natalizumab treatment and to investigate the association with disease activity. We find that subgroups of autoreactive T cells are retained in peripheral blood, in particular MOG-reactive CD4+ T cells expressing MCAM-1. The expression of MCAM-1 or ALCAM on CD4+ T cells was, however, not clearly associated with disease activity (clinical or MRI) during natalizumab treatment. We confirm upregulation of MCAM-1 on CD4+ T cells during natalizumab treatment while VLA-4 is downregulated.

KW - Adult

KW - Aged

KW - CD146 Antigen/biosynthesis

KW - CD4-Positive T-Lymphocytes/drug effects

KW - Cohort Studies

KW - Female

KW - Gene Expression

KW - Humans

KW - Immunologic Factors/administration & dosage

KW - Infusions, Intravenous

KW - Male

KW - Middle Aged

KW - Multiple Sclerosis/blood

KW - Natalizumab/administration & dosage

KW - Prospective Studies

KW - Young Adult

U2 - 10.1016/j.jneuroim.2019.577085

DO - 10.1016/j.jneuroim.2019.577085

M3 - Journal article

C2 - 31655423

VL - 337

SP - 577085

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

ER -

ID: 61518900